

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

New Programs

- GUOTEVER:** Everolimus for Tuberous Sclerosis Complex-Associated High Risk Renal Angiomyolipoma
- ULYMOGA:** Mogamulizumab for Treatment of Mycosis Fungoides and Sézary Syndrome
- LYCHOPO, LYCVPO, LYGDPO:** Obinutuzumab in Combination with Chemotherapy for Rituximab-Refractory Follicular Lymphoma
- LYTEM:** Temozolomide for Relapsed Central Nervous System Lymphoma

Revised Programs: GIAVCAP, GIPAVCAP

Cancer Drug Manual®

- New:** Dostarlimab, Nelarabine **Revised:** Blinatumomab, Mogamulizumab

Clinical Care Pathways for Health Professionals

- Consultation on Tumour-Specific Pathways

Drug Update

- Dermatological Toxicities Management of Anti-EGFR Monoclonal Antibodies – Prescription Set

Benefit Drug List

- New:** GUOTEVER, LYCHOPO, LYCVPO, LYGDPO, ULYMOGA, LYTEM **Revised:** GIAVCAP **Deleted:** GIPAVCAP

NEW Protocols, PPOs and Patient Handouts

- GU** GUOTEVER **LY** LYCHOPO, LYCVPO, LYGDPO, ULYMOGA, LYTEM

REVISED Protocols, PPOs and Patient Handouts

- GI** GIA, GIAJNIV, GIATZB, GIAVCAP, GIAVCAPB, GIAVCETIR, GIAVDOC, UGIAVPANEN, GIAVPANI, UGIAVPEM, UGIAVPEM6, GIBAJCAP, UGICABO, GICAPOX, GICIRB, GICOXB, GIEFFOXRT, GIENACTRT, GIFFIRB, GIFFIRPAN, GIFFOXB, GIFFOXPAN, GIFIRINOX, GIFOLFIRI, GIFUC, GIGAJCOX, GIGAJCPT, GIGAJFFOX, GIGAVCCT, GIGAVCFT, GIGAVCOX, GIGAVCOXN, GIGAVCOXP, GIGAVCOXT, GIGAVFFOX, GIGAVFFOXN, GIGAVFFOXP, GIGAVFFOXT, GIGAVRAMT, GIGAVTRM, GIGAVTRFT, GIGECC, GIGFLODOC, GIGFOLFIRI, GILEN, GIPAJFIROX, GIPAJGCAP, GIPAJGEM, GIPAVFFIRI, GIPAVFFOX, GIPGEM, GIPGEMABR, GIREGO, GISORAF | **GU** GUEVER | **LY** LYALEM, LYOBEND, LYBENDO, ULYVENETO, LYVENETOR, LYVENOB | **MY** MYCARDEX, MYCARLD, MYMPBOR

Resources and Contact Information

Editor's Choice

New Programs

Effective 01 July 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Genitourinary

Everolimus for Tuberous Sclerosis Complex-Associated High Risk Renal Angiomyolipomas (GUOTEVER) – The BC Cancer Genitourinary Tumour Group is introducing everolimus for treatment of patients with renal angiomyolipomas associated with tuberous sclerosis complex (TSC), a rare genetic disorder characterized by a high prevalence of benign tumours affecting multiple organ systems. Everolimus is an oral mTOR inhibitor that targets over-activation of the mTOR signalling pathway caused by mutations associated with TSC. In the phase III EXIST-2 trial, everolimus was

New Programs

associated with response rate of 58% and some degree of shrinkage in 97% of patients. Everolimus is recommended for TSC-associated renal angiomyolipomas in the International and Canadian guidelines.[1-3]

Lymphoma

Mogamulizumab for Treatment of Mycosis Fungoides and Sézary Syndrome (ULYMOGA) – The BC Cancer Lymphoma Tumour Group is introducing mogamulizumab for the treatment of mycosis fungoides and Sézary syndrome in patients who have failed at least one prior systemic therapy. Currently, there is no standard of care for the treatment of this patient population. Mogamulizumab is a new monoclonal antibody targeting the CCR4 receptor overexpressed in some T-cell malignancies. In the phase III MAVORIC study compared to vorinostat (not commonly used in Canada), mogamulizumab was shown to improve progression-free survival and overall response rate. Common adverse events include infusion-related reactions, drug eruption, diarrhea, and fatigue.[4]

Obinutuzumab in Combination with Chemotherapy for Rituximab-Refractory Follicular Lymphoma (LYCHOPO, LYCVPO, LYGDPO) – The BC Cancer Lymphoma Tumour Group is introducing obinutuzumab in combination with standard chemotherapy regimens for patients with follicular lymphoma who are refractory to rituximab. Obinutuzumab with bendamustine has been shown to benefit patients with rituximab-refractory follicular lymphoma. However, patients may be ineligible for second line bendamustine because bendamustine with rituximab is the current standard first line therapy of follicular lymphoma.[5]

Temozolomide for Relapsed Central Nervous System Lymphoma (LYTEM) – The BC Cancer Lymphoma Tumour Group is introducing temozolomide for primary and secondary central nervous system (CNS) lymphomas with progressive disease after standard frontline therapies such as high-dose methotrexate or radiation. Temozolomide has been shown to be active in relapsed CNS lymphoma in phase II studies, with a complete response of 29% in one study.[6,7]

References

1. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. *PLoS One*. 2017;12(8):e0180939. Published 2017 Aug 9. doi:10.1371/journal.pone.0180939
2. Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. *Pediatr Neurol* 2021;123:50-66.
3. Tuberous Sclerosis Canada. Consensus guidelines for diagnosis, surveillance and management of tuberous sclerosis complex. Available at: <https://www.tscanada.ca/wp-content/uploads/2014/12/TSCanada-TREATMENT-CONSENSUS-GUIDELINES.pdf>.
4. CADTH Review Mogamulizumab (Poteligeo) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies* August 2022; 2(8): 1-19.
5. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. *Lancet Oncol* 2016;17(8):1081-1093.
6. Makino K, Nakamura H, Hide T, Kuratsu J. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. *J Neurooncol* 2012;106(1):155-60.
7. Reni M, Zaja F, et al. Temozolomide as salvage treatment in primary brain lymphomas. *Br J Cancer* 2007;96(6):864-7.

Revised Programs

Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine (GIAVCAP) – The GIAVCAP protocol has been revised to include indication for pancreatic cancer, which was previously under the protocol GIPAVCAP.

All documents are available in the [Cancer Drug Manual[©]](#) on the BC Cancer website.

New Documents

Note that the following drugs are not BC Cancer Benefit Drugs and require application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monographs, Patient Handout, and Chemotherapy Preparation and Stability Chart entries are made available for reference only.

The **Dostarlimab Interim Monograph** has been developed. **Dostarlimab** is a humanized IgG4 monoclonal antibody immune checkpoint inhibitor that binds to programmed death receptor-1 (PD-1). Dostarlimab is used in the treatment of endometrial cancer. The usual dose is 500 mg IV given once every 3 weeks.

Highlights from this document include:

- dostarlimab can cause severe and fatal immune-mediated adverse reactions
 - management of infusion-related reactions may require withholding the dose, 50% rate reduction, and premedication
 - dose reduction is not recommended; toxicity is managed with dose delays or drug discontinuation

Dostarlimab has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

The **Nelarabine Interim Monograph** and **Patient Handout** have been developed. Expert review was provided by Dr. Amanda Li (hematologist/oncologist, BC Children's) and Jennifer Kendrick (clinical pharmacy specialist, BC Children's). Nelarabine is a nucleoside antimetabolite. It is used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. The usual dosing is 1500 mg/m² IV on days 1, 3, and 5 every 3 weeks.

Highlights from these documents include:

- hematologic toxicity is frequently reported
- a wide array of neurologic adverse events may occur, some of which are severe, irreversible and fatal
- rhabdomyolysis is a rare but serious side effect; patients should report any unexplained muscle pain, tenderness, or weakness immediately

Nelarabine has been added to the **Chemotherapy Preparation and Stability Chart** and has been previously evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Blinatumomab Patient Handout

Introduction: updated explanation for drug mechanism to align with language used with other bispecific T-cell engagers

Cancer Drug Manual[©]

Side Effects table: updated preamble and added cytokine release syndrome
Throughout: updated per current template language

Mogamulizumab Monograph and Patient Handout

Parenteral Administration: bolded and italicized BC Cancer standard administration


Dosage Guidelines: bolded and italicized BC Cancer standard dosing and new BC Cancer protocol ULYMOGA

Patient Handout: updated wording throughout per current template standard

Clinical Care Pathways for Health Professionals

Consultation on Tumour-Specific Pathways

BC Cancer now has an overarching pathway of care for all patients with cancer and 5 tumour specific pathways. [Clinical Care Pathways \(bccancer.bc.ca\)](https://bccancer.bc.ca)



BC Cancer's Tumour Groups are collaborating to create Tumour-Specific Cancer Care Pathways to support all health care professionals in the delivery of high-quality care consistently, efficiently, and efficaciously to all patients with cancer.

Developed through rigorous methodologies by multidisciplinary teams across BC's health authorities, each pathway is tailored to specific types of tumours and features references, hyperlinks and notes for clinicians. The goal is to facilitate easy identification of a patient's current care stage and provide guidance for next steps. Each pathway aligns with the stages of the Overarching Clinical Care Pathway: Pre-diagnosis, Diagnosis, Treatment, Post Treatment Care & Survivorship, Recurrent or Progressive Disease and End of Life Care.

Clinical Care Pathways for Health Professionals

Please share with your teams and feel free to provide feedback. A feedback form is located at the bottom of the Consultation on Tumour-Specific Pathways page. [Consultation on Tumour-Specific Pathways \(bccancer.bc.ca\)](https://www.bccancer.bc.ca/consultation-on-tumour-specific-pathways)

Any questions? Please email TGCoordinator@bccancer.bc.ca.

Drug Update

Management of Dermatological Toxicities of Anti-EGFR Monoclonal Antibodies – Prescription Set

In an initiative to standardize management of dermatological toxicities associated with anti-EGFR monoclonal antibody therapy, a prescription set for supportive care medications has been added to webpages of the panitumumab and cetuximab protocols on the Gastrointestinal, Head and Neck and Skin / Melanoma tumour groups. The prescription outlines treatment recommendations for the management of rash, pruritus, mucositis and paronychia, based on peer-reviewed supporting evidence and availability of marketed products/formulations.

Benefit Drug List

New Programs

Effective 01 July 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Therapy for Tuberous Sclerosis Complex-Associated High Risk Renal Angiomyolipomas using Everolimus	GUOTEVER	Class I
Treatment of ritUXimab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vinCRISTine, predniSONE, and oBINutuzumab	LYCHOPO	Class I
Treatment of ritUXimab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRISTine, predniSONE and oBINutuzumab	LYCVPO	Class I
Treatment of ritUXimab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and oBINutuzumab	LYGDPO	Class I
Treatment of Mycosis Fungoides and Sézary Syndrome with Mogamulizumab	ULYMOGA	Restricted
Treatment of Relapsed CNS Lymphoma using Temozolomide	LYTEM	Class I

Benefit Drug List

Revised Programs

Effective 1 July 2024, the following treatment program has been revised in the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine	GIAVCAP	Class I
Treatment of riTUXimab refractory Follicular Lymphoma (FL) with oBINutuzumab in combination with Bendamustine	LYBENDO (previously LYOBEND)	Class I

Deleted Programs

Effective 1 July 2024, the following treatment program has been deleted from the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine	GIPAVCAP	Class I

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Code	Protocol Title	Protocol	PPPO	Handout
GUOTEVER	Therapy for Tuberous Sclerosis Complex-Associated High Risk Renal Angiomyolipomas using Everolimus	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
LYCHOPO	Treatment of riTUXimab-refractory Follicular Lymphoma with DOXOrubicin, Cyclophosphamide, vincristine, predniSONE, and oBINutuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

NEW Protocols, PPPOs and Patient Handouts (new documents checked)

Code	Protocol Title	Protocol	PPPO	Handout
LYCVPO	Treatment of ritUXimab-refractory Follicular Lymphoma with Cyclophosphamide, vinCRISTine, predniSONE and oBINutuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
LYGDPO	Treatment of ritUXimab-refractory Follicular Lymphoma with Gemcitabine, Dexamethasone, Platinum and oBINutuzumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
ULYMOGA	Treatment of Mycosis Fungoides and Sézary Syndrome with Mogamulizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
LYTEM	Treatment of Relapsed CNS Lymphoma using Temozolomide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GI Gastrointestinal				
GIA	Palliative Therapy for Hepatocellular Carcinoma using DOXOrubicin	<i>Title, eligibility and emetogenic risk category clarified, tests and link in footer updated</i>	<i>Tests updated</i>	--
GIAJNIV	Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer using Nivolumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIATZB	First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIAVCAP	Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine	<i>Title, eligibility, tests, emetogenic risk category, and references updated</i>	<i>Tests updated</i>	--
GIAVCAPB	Palliative Therapy of Metastatic Colorectal Cancer using Capecitabine and Bevacizumab	<i>Tests and treatment duration updated, emetogenic risk category clarified</i>	<i>Bevacizumab flush removed, tests updated</i>	--
GIAVCETIR	Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan	<i>Tests and treatment duration updated, emetogenic risk category clarified</i>	<i>Tests updated</i>	--
GIAVDOC	Palliative Treatment of Metastatic Esophagogastric Adenocarcinoma with DOCEtaxel	<i>Eligibility clarified, tests, precautions, and link in footer updated</i>	<i>Pre-chemo metrics and tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
UGIAVPANEN	Treatment of BRAF V600E - Mutated Metastatic Colorectal Cancer using PANitumumab and Encorafenib	<i>Tests and uveitis management updated</i>	<i>Tests updated</i>	--
GIAVPANI	Palliative Third Line Treatment of Metastatic Colorectal Cancer Using PANitumumab	<i>Tests updated</i>	<i>Tests updated</i>	--
UGIAVPEM	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
UGIAVPEM6	First-Line Treatment of dMMR/MSI-H Metastatic Colorectal Cancer using 6-Weekly Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIBAJCAP	Adjuvant Therapy of Biliary Cancer using Capecitabine	<i>Tests and emetogenic risk category clarified</i>	<i>Tests updated</i>	--
UGICABO	Treatment of Advanced Hepatocellular Carcinoma using Cabozantinib	<i>Tests updated</i>	<i>Pre-chemo metrics removed, tests updated</i>	--
GICAPOX	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Oxaliplatin and Capecitabine	<i>Title, eligibility, tests, emetogenic risk category and references updated</i>	<i>Tests updated</i>	--
GICIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Bevacizumab and Capecitabine	<i>Tests updated, emetogenic risk category clarified</i>	<i>Bevacizumab volume for flush removed, tests updated</i>	--
GICOXB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine	<i>Tests and treatment duration updated, emetogenic risk category clarified</i>	<i>Bevacizumab volume for flush removed, tests updated</i>	--
GIEFFOXRT	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIENACTRT	Neoadjuvant Treatment of Esophageal and Gastroesophageal Carcinomas using CARBOplatin, PACLitaxel and Radiation Therapy	<i>Eligibility clarified, tests and link in footer updated</i>	<i>Tests updated</i>	--
GIFIRB	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin, and Bevacizumab	<i>Tests updated, emetogenic risk category clarified</i>	<i>Bevacizumab volume for flush removed, tests updated</i>	--
GIFIRPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin, and PANitumumab	<i>Tests updated and emetogenic risk category clarified</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GIFFOX B	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Bevacizumab	<i>Tests updated and emetogenic risk category clarified</i>	<i>Bevacizumab volume for flush removed, tests updated</i>	--
GIFFOX PAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and PANitumumab	<i>Eligibility and tests updated, emetogenic risk category clarified</i>	<i>Tests updated</i>	--
GIFIRINOX	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Tests updated</i>	<i>Tests updated</i>	--
GIFOLFIRI	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Tests and link in footer updated, emetogenic risk category clarified,</i>	<i>Tests updated</i>	--
GIFUC	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder, Pancreas Carcinoma and Cholangiocarcinoma) and Metastatic Anal using Infusional Fluorouracil and CISplatin	<i>Eligibility and emetogenic risk category clarified, tests and link in footer updated</i>	<i>Tests updated</i>	--
GIGAJCOX	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAJCPRT	Adjuvant Chemotherapy of Gastric Cancer patients with Completely Resected Gastric Cancer using CISplatin and Capecitabine and Radiation Therapy	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
GIGAJFFOX	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Eligibility and emetogenic risk category clarified, tests updated, physician contact updated</i>	<i>Tests updated</i>	--
GIGAVCCT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using CISplatin, Capecitabine and Trastuzumab	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVCFT	Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using CISplatin, Infusional Fluorouracil and Trastuzumab	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIGAVCOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Carcinoma using Capecitabine, and Oxaliplatin	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVCOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIGAVCOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Capecitabine and Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIGAVCOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin, and Trastuzumab	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVFFOX	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Carcinoma using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVFFOXN	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	<i>Tests updated</i>	<i>Tests updated</i>	--
GIGAVFFOXP	First-Line Treatment of Locally Advanced or Metastatic Gastroesophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Pembrolizumab	<i>Tests and dose modifications updated</i>	<i>Tests updated</i>	--
GIGAVFFOXT	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin, and Trastuzumab	<i>Eligibility and emetogenic risk category clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVRAMT	Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly PAclitaxel and Ramucirumab	<i>Title, precautions and physician contact updated, eligibility clarified</i>	<i>Separate filter comment clarified, tests updated</i>	--
GIGAVTR	Continuation of Palliative Treatment of Metastatic or Inoperable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma using Trastuzumab	<i>Eligibility and treatment duration clarified, tests updated</i>	<i>Tests updated</i>	--
GIGAVTRFT	Third- or Later-Line Therapy of Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
GIGECC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, CISplatin and Capecitabine	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIGFLODOC	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using DOCEtaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin	<i>Eligibility clarified, tests updated</i>	<i>Tests updated</i>	--
GIGFOLFIRI	Second or Third Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma or Esophageal Squamous Cell Carcinoma using Irinotecan, Fluorouracil and Leucovorin	<i>Title, eligibility, tests, emetogenic risk category, and references updated</i>	<i>Tests updated</i>	--
GILEN	Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	<i>Eligibility, tests and emetogenic risk category updated</i>	<i>Pre-chemo metrics and dispense quantity clarified, tests updated</i>	--
GIPAJFIROX	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Tests updated</i>	<i>Tests updated</i>	--
GIPAJGCAP	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine	<i>Tests updated</i>	<i>Treatment clarified, tests updated</i>	--
GIPAJGEM	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma Using Gemcitabine	<i>Tests and link in footer updated, emetogenic risk category and treatment clarified</i>	<i>Treatment clarified, tests updated</i>	--
GIPAVFFIRI	Second Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Tests updated, emetogenic risk category clarified</i>	<i>Tests updated</i>	--
GIPAVFFOX	Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	<i>Title, eligibility, tests, emetogenic risk category, and references updated</i>	<i>Tests updated</i>	--
GIPGEM	Palliative Chemotherapy for Pancreatic Adenocarcinoma, Gallbladder Cancer, and Cholangiocarcinoma Using Gemcitabine	<i>Tests and link in footer updated, emetogenic risk category and treatment clarified</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Code	Protocol Title	Protocol	PPPO	Handout
GIPGEMABR	First Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel NAB (ABRAXANE) and Gemcitabine	<i>Tests updated, emetogenic risk category clarified</i>	<i>Tests updated</i>	--
GIREGO	Treatment of Advanced Hepatocellular Carcinoma Using Regorafenib	<i>Tests updated</i>	<i>Blood pressure removed from pre-chemo metrics, dispense quantity clarified, tests updated</i>	--
GISORAF	Therapy for Advanced Hepatocellular Carcinoma using SORafenib	<i>Tests updated and treatment duration clarified</i>	<i>Dispense quantity clarified, tests updated</i>	--
GU Genitourinary				
GUEVER	Therapy for Advanced Renal Cancer using Everolimus	<i>Eligibility clarified, tests, premedications, dose modifications, and precautions updated</i>	<i>Tests updated</i>	--
LY Lymphoma				
LYALEM	Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)	<i>Clarified Clinigen MabCampath Distribution Program rationale</i>	<i>Clarified Clinigen MabCampath Distribution Program rationale</i>	--
LYBENDO (Previously LYOBEND)	Treatment of ritUXimab refractory Follicular Lymphoma (FL) with oBINutuzumab in combination with Bendamustine	<i>Protocol code, tests, supportive medications, dose modifications, and precautions updated</i>	<i>Protocol code, pre-chemo metrics and tests updated</i>	--
ULYVENETO	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax	<i>Tests, supportive medications and precautions updated, contact pharmacist removed</i>	<i>Tests updated and allopurinol prescription removed</i>	--
LYVENETOR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Venetoclax and ritUXimab	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated and allopurinol prescription removed</i>	--
LYVENOB	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and oBINutuzumab	<i>Tests updated, contact pharmacist removed</i>	<i>Tests updated and allopurinol prescription removed</i>	--
MY Myeloma				
MYCARDEX	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide	<i>Premedications and treatment clarified</i>	<i>Premedications clarified</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
MYCARLD	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	<i>Premedications and treatment clarified</i>	<i>Premedications clarified</i>	--
MYMPBOR	Treatment of Multiple Myeloma using Melphalan, predniSONE and Weekly Bortezomib With the Option of Substituting Cyclophosphamide for Melphalan	<i>Steroid options updated</i>	--	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638	nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@ehcnet.phsa.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247	mclin@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jelena Mucovic, BScPharm (Assistant Editor)
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN